that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid
data from a large randomized, controlled clinical trial to determine whether this experimental
treatment is safe and can improve clinical outcomes.”

Thanks much,
Kathy

Kathy Stover

Branch Chief

News and Science Writing Branch

National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS

31 Center Drive, Room 7A17E

Bethesda, MD 20892

Phone: (WY

E-mail OG

NIAID Media Line: (301) 402-1663
